{"sent_idx": "119", "frame_idx": "13", "ev": "Median response for interferon \u03b3 was 232 spots per 106 cells with 1011 VP compared with 57 spots per 106 cells with placebo (p<0\u00b70001).", "icos": [["1", "placebo", "interferon \u03b3", "Median response"]], "sample": "x"}
{"sent_idx": "125", "frame_idx": "16", "ev": "However, after one boost with inactivated H5N1 vaccine, Ad4-H5-Vtn recipients had significantly higher occurrence of seroconversion than did placebo recipients: 80% for HAI and 67% for microneutralisation in vaccinees, compared with 36% and 33%, respectively, in placebo recipients (tables 3, 4; p=0\u00b70003 for HAI, p=0\u00b7006 for microneutralisation).", "icos": [["1", "placebo", "inactivated H5N1 vaccine", "occurrence of seroconversion"]], "sample": "x"}
{"sent_idx": "18", "frame_idx": "0", "ev": "The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16\u00b78%] of 125 vs one [2\u00b74%] of 41, p=0\u00b7017; 24 [19\u00b72%] of 125 vs two [4\u00b79%] of 41, p=0\u00b7027; 41 [32\u00b78%] of 125 vs six [14\u00b76%] of 41, p=0\u00b7028; respectively).", "icos": [["0.99731183", "placebo", "H5N1 vaccines", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.99531245", "placebo", "Ad4 and Ad7 vaccines", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.9950618", "placebo", "Ad4 - H5 - Vtn vector vaccine", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.9946944", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.99446636", "placebo", "inactivated parenteral H5N1 vaccine .", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"]], "sample": "c"}
{"sent_idx": "38", "frame_idx": "2", "ev": "The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16\u00b78%] of 125 vs one [2\u00b74%] of 41, p=0\u00b7017; 24 [19\u00b72%] of 125 vs two [4\u00b79%] of 41, p=0\u00b7027; 41 [32\u00b78%] of 125 vs six [14\u00b76%] of 41, p=0\u00b7028; respectively).", "icos": [["0.99731183", "placebo", "H5N1 vaccines", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.99531245", "placebo", "Ad4 and Ad7 vaccines", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.9950618", "placebo", "Ad4 - H5 - Vtn vector vaccine", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.9946944", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.99446636", "placebo", "inactivated parenteral H5N1 vaccine .", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"]], "sample": "c"}
{"sent_idx": "96", "frame_idx": "4", "ev": "Headache was the only reactogenicity symptom reported more frequently in vaccinees than placebo recipients after the first vaccination (p=0\u00b7046; table 1).", "icos": [["0.99718684", "placebo", "Ad4 and Ad7 vaccines", "Headache"], ["0.9965419", "placebo", "H5N1 vaccines", "Headache"], ["0.9965321", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "Headache"], ["0.9964227", "placebo", "inactivated parenteral H5N1 vaccine .", "Headache"], ["0.99632794", "placebo", "Ad4 - H5 - Vtn vector vaccine", "Headache"]], "sample": "c"}
{"sent_idx": "97", "frame_idx": "5", "ev": "The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16\u00b78%] of 125 vs one [2\u00b74%] of 41, p=0\u00b7017; 24 [19\u00b72%] of 125 vs two [4\u00b79%] of 41, p=0\u00b7027; 41 [32\u00b78%] of 125 vs six [14\u00b76%] of 41, p=0\u00b7028; respectively; appendix).", "icos": [["0.99731183", "placebo", "H5N1 vaccines", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.99531245", "placebo", "Ad4 and Ad7 vaccines", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.9950618", "placebo", "Ad4 - H5 - Vtn vector vaccine", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.9946944", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"], ["0.99446636", "placebo", "inactivated parenteral H5N1 vaccine .", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion"]], "sample": "c"}
{"sent_idx": "99", "frame_idx": "6", "ev": "After the H5N1 boost, systemic reactogenicity was much the same in Ad4-H5-Vtn and placebo recipients (appendix).", "icos": [["0.9773377", "placebo", "Ad4 - H5 - Vtn vaccine", "systemic reactogenicity"], ["0.96975327", "placebo", "H5N1 vaccines", "systemic reactogenicity"], ["0.9500728", "placebo", "Ad4 - H5 - Vtn vector vaccine", "systemic reactogenicity"], ["0.9368233", "placebo", "oral adenovirus serotype 4 vector vaccine candidate ( Ad4 - H5 - Vtn )", "systemic reactogenicity"], ["0.92629653", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "systemic reactogenicity"]], "sample": "c"}
{"sent_idx": "100", "frame_idx": "7", "ev": "Local reactogenicity after boost was more common in Ad4-H5-Vtn vaccinees: injection site pain (all mild) was reported by 17 (20\u00b75%) of 83 vaccinees and none of 22 placebo recipients (p=0\u00b7020).", "icos": [["0.99277264", "placebo", "inactivated parenteral H5N1 vaccine .", "Local reactogenicity"], ["0.9911849", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "Local reactogenicity"], ["0.98793507", "placebo", "inactivated H5N1 vaccine", "Local reactogenicity"], ["0.9873921", "placebo", "H5N1 vaccines", "Local reactogenicity"], ["0.9873527", "placebo", "Vaccine or placebo", "Local reactogenicity"]], "sample": "c"}
{"sent_idx": "100", "frame_idx": "8", "ev": "Local reactogenicity after boost was more common in Ad4-H5-Vtn vaccinees: injection site pain (all mild) was reported by 17 (20\u00b75%) of 83 vaccinees and none of 22 placebo recipients (p=0\u00b7020).", "icos": [["0.99396557", "placebo", "inactivated parenteral H5N1 vaccine .", "injection site pain"], ["0.9922191", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "injection site pain"], ["0.9894394", "placebo", "inactivated H5N1 vaccine", "injection site pain"], ["0.9894108", "placebo", "Vaccine or placebo", "injection site pain"], ["0.9894108", "placebo", "vaccine or placebo", "injection site pain"]], "sample": "c"}
{"sent_idx": "101", "frame_idx": "9", "ev": "However, the occurrence of tenderness at the injection site was similar between groups: 24 (28\u00b79%) of 83 vaccinees and five (22\u00b77%) of 22 placebo recipients.", "icos": [["0.99664056", "placebo", "inactivated parenteral H5N1 vaccine .", "occurrence of tenderness at the injection site"], ["0.99635136", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "occurrence of tenderness at the injection site"], ["0.9961265", "placebo", "H5N1 vaccines", "occurrence of tenderness at the injection site"], ["0.9960615", "placebo", "Ad4 - H5 - Vtn vaccine", "occurrence of tenderness at the injection site"], ["0.9958748", "placebo", "inactivated H5N1 vaccine", "occurrence of tenderness at the injection site"]], "sample": "c"}
{"sent_idx": "116", "frame_idx": "12", "ev": "Interferon-\u03b3 T-cell response to recombinant H5 haemagglutinin protein or peptide pools ranged from 38% (nine of 24 vaccinees) with 107 VP to 70% (16 of 23 vaccines) with 1011 VP, compared with only 5% (two of 41) of placebo recipients (figure 2).", "icos": [["0.9990941", "placebo", "H5N1 vaccines", "Interferon - \u03b3 T - cell response to recombinant H5 haemagglutinin protein or peptide pools"], ["0.9981933", "placebo", "Ad4 and Ad7 vaccines", "Interferon - \u03b3 T - cell response to recombinant H5 haemagglutinin protein or peptide pools"], ["0.9980009", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "Interferon - \u03b3 T - cell response to recombinant H5 haemagglutinin protein or peptide pools"], ["0.99787104", "placebo", "inactivated parenteral H5N1 vaccine .", "Interferon - \u03b3 T - cell response to recombinant H5 haemagglutinin protein or peptide pools"], ["0.99709225", "placebo", "Ad4 - H5 - Vtn vaccine", "Interferon - \u03b3 T - cell response to recombinant H5 haemagglutinin protein or peptide pools"]], "sample": "c"}
{"sent_idx": "120", "frame_idx": "14", "ev": "Median response for interleukin 2 was 345 spots per 106 cells with 1011 VP compared with 111 spots per 106 for placebo (p<0\u00b70001).", "icos": [["0.99543697", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "Median response for interleukin 2"], ["0.99408555", "placebo", "H5N1 or H5N2", "Median response for interleukin 2"], ["0.994013", "placebo", "Ad4 - H5 - Vtn", "Median response for interleukin 2"], ["0.99167246", "placebo", "Ad4 - H5 - Vtn vaccine", "Median response for interleukin 2"], ["0.9912719", "placebo", "Ad4 - H5 - Vtn or placebo .", "Median response for interleukin 2"]], "sample": "c"}
{"sent_idx": "124", "frame_idx": "15", "ev": "Only five vaccinees and no placebo recipients achieved seroprotection (HAI titre \u226540).", "icos": [["0.9939122", "placebo", "H5N1 vaccines", "seroprotection"], ["0.98991895", "placebo", "inactivated parenteral H5N1 vaccine .", "seroprotection"], ["0.98925567", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "seroprotection"], ["0.9891104", "placebo", "inactivated H5N1 vaccine", "seroprotection"], ["0.98901725", "placebo", "Ad4 and Ad7 vaccines", "seroprotection"]], "sample": "c"}
{"sent_idx": "127", "frame_idx": "17", "ev": "Post-boost HAI GMT for all vaccine cohorts was 56 (range 28\u2013135), compared with 13 for the placebo group (tables 3, 4; p<0\u00b70001 for all groups vs placebo; GMT 10\u00b77, 95% CI 5\u00b75\u201320\u00b79).", "icos": [["0.98853135", "placebo", "H5N1 vaccines", "Post - boost HAI GMT"], ["0.9850433", "placebo", "Vaccine or placebo", "Post - boost HAI GMT"], ["0.9850433", "placebo", "vaccine or placebo", "Post - boost HAI GMT"], ["0.98477143", "placebo", "Ad4 vector vaccines", "Post - boost HAI GMT"], ["0.9843322", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "Post - boost HAI GMT"]], "sample": "c"}
{"sent_idx": "128", "frame_idx": "18", "ev": "Seroprotection ranged from 61% to 89% in vaccine groups, compared with 18% for placebo (tables 3, 4).", "icos": [["0.9967527", "placebo", "H5N1 vaccines", "Seroprotection"], ["0.99571085", "placebo", "Ad4 and Ad7 vaccines", "Seroprotection"], ["0.9917025", "placebo", "inactivated parenteral H5N1 vaccine .", "Seroprotection"], ["0.9907171", "placebo", "inactivated H5N1 vaccine", "Seroprotection"], ["0.9900024", "placebo", "inactivated parenteral subvirion H5N1 vaccine", "Seroprotection"]], "sample": "c"}
{"sent_idx": "154", "frame_idx": "26", "ev": "The Ad4-H5-Vtn vaccine induced haemagglutinin-specific cellular immune responses but only primed for haemagglutinin-specific antibody responses.", "icos": [["0.99963737", "Ad4 - H5 - Vtn vaccine", "Ad4 - H5 - Vtn", "haemagglutinin - specific cellular immune responses"], ["0.9996227", "Ad4 - H5 - Vtn vaccine", "Ad4 - H5", "haemagglutinin - specific cellular immune responses"], ["0.9996124", "Ad4 - H5 - Vtn vaccine", "Ad4 - H5 - Vtn vaccine", "haemagglutinin - specific cellular immune responses"], ["0.99956495", "Ad4 - H5 - Vtn vaccine", "Ad4 - H5 - Vtn vector", "haemagglutinin - specific cellular immune responses"], ["0.99951994", "Ad4 - H5 - Vtn vaccine", "Ad4 - H5 - Vtn vector vaccine", "haemagglutinin - specific cellular immune responses"]], "sample": "c"}
{"sent_idx": "170", "frame_idx": "27", "ev": "Oral administration of the Ad4-H5-Vtn vector efficiently primed for HAI antibody responses as evidenced by the robust antibody responses to boosting with inactivated parenteral H5N1 vaccine.", "icos": [["0.99962914", "Ad4 - H5 - Vtn vector", "Ad4 - H5 - Vtn", "HAI antibody responses"], ["0.9996209", "Ad4 - H5 - Vtn vector", "Ad4 - H5", "HAI antibody responses"], ["0.9996076", "Ad4 - H5 - Vtn vector", "Ad4 - H5 - Vtn vector", "HAI antibody responses"], ["0.99950373", "Ad4 - H5 - Vtn vector", "Ad4 - H5 - Vtn vaccine", "HAI antibody responses"], ["0.9994931", "Ad4 - H5 - Vtn vector", "Ad4 - H5 - Vtn vector vaccine", "HAI antibody responses"]], "sample": "c"}
